AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30227301
Drug: Glutathione 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione 40 mg L-1
Trial: 30227301
Drug: Glutathione 0
RxNorm normalized name: glutathione 0.184 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione 0 mg L-1 (control)
Trial: 26946727
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (0.3 g twice a day), Methotrexate (10 mg once a week), Folic acid (5 mg once a week)
Trial: 21795756
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate supplementation (target venous bicarbonate 29 mmol/L)
Trial: 21795756
Drug: Previous sodium
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous sodium bicarbonate treatment (target 24 mmol/L)
Trial: 19955221
Drug: Joint lavage
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint lavage combined with IA steroid injection
Trial: 10445610
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 2 mg x day(-1)
Trial: 476023
Drug: Clotrimazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (100 mg/day for 6 days)
Trial: 476023
Drug: Miconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole (100 mg/day for 14 days)
Trial: 476023
Drug: Miconazole (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole (100 mg twice daily for 7 days)
Trial: 31987323
Drug: 160 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/kg VE
Trial: 31987323
Drug: 320 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg/kg VE
Trial: 31987323
Drug: 640 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 640 mg/kg VE
Trial: 24062180
Drug: Saroglitazar (ZYH1)
RxNorm normalized name: Saroglitazar
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar (ZYH1) at doses of 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128 mg
Trial: 24062180
Drug: Saroglitazar (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar (1 mg)
Trial: 24062180
Drug: Saroglitazar (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar (up to 128 mg)
Trial: 19124098
Drug: Prophylactic cement
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cement injection into non-fractured vertebra adjacent to fractured vertebra
Trial: 19124098
Drug: Non-prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-prophylactic treatment (no cement injection)
Trial: 11694667
Drug: Atomoxetine 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 1.8 mg/kg/day
Trial: 11694667
Drug: Atomoxetine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 0.5 mg/kg/day
Trial: 11694667
Drug: Atomoxetine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (all doses)
Trial: 8981385
Drug: Haloperidol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2 mg p.o.)
Trial: 8981385
Drug: Haloperidol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2 mg p.o.) + Scopolamine (0.5 mg i.v.)
Trial: 8981385
Drug: Metergoline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metergoline (4 mg p.o.) + Scopolamine (0.5 mg i.v.)
Trial: 8518376
Drug: Computer-assisted continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted continuous infusion (CACI)
Trial: 8518376
Drug: Manual controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual controlled infusion (MCI)
Trial: 2881575
Drug: Topical dimethindene
RxNorm normalized name: dimethindene
DrugBank: Dimetindene (DB08801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dimethindene maleate
Trial: 31236568
Drug: COBRA-Slim (MTX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA-Slim (MTX, prednisone step-down from 30 mg)
Trial: 31236568
Drug: COBRA-Classic (MTX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA-Classic (MTX, sulfasalazine, prednisone step-down from 60 mg)
Trial: 31236568
Drug: COBRA-Avant-Garde (MTX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA-Avant-Garde (MTX, leflunomide, prednisone step-down from 30 mg)
Trial: 27834686
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg) and folic acid (0.8 mg)
Trial: 26623405
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron + 8 mg dexamethasone (Group OD)
Trial: 23993109
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (bemiparin) for 10 days at a prophylactic dose, early ambulation, and compression therapy for 3 months
Trial: 23993109
Drug: Early ambulation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early ambulation and compression therapy alone
Trial: 18194979
Drug: Valsartan (80-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80-160 mg/d)
Trial: 18194979
Drug: Metoprolol (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50-100 mg/d)
Trial: 8970342
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (800 micrograms twice a day)
Trial: 1306041
Drug: Lignocaine 3
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 3 ml 1%
Trial: 1306041
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 3 ml
Trial: 21288803
Drug: Pentavac(®) (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavac(®) (new vaccine)
Trial: 3303244
Drug: Ramified amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramified amino acids (24 g in a 750 ml solution) infused daily for 10 days
Trial: 3303244
Drug: Sorbitol (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (5% solution, 750 ml) infused daily for 10 days
Trial: 28776922
Drug: Subcutaneous exendin
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous exendin (9-39) injection
Trial: 16464887
Drug: On-line haemodiafiltration
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-line haemodiafiltration with acetate (3 mmol/l)
Trial: 10610746
Drug: Oral amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amiodarone 400 mg/day for 1 month before and 200 mg/day for 2 months after cardioversion
Trial: 10610746
Drug: Oral diltiazem
RxNorm normalized name: diltiazem Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diltiazem 180 mg/day for 1 month before and 2 months after cardioversion and potassium infusion
Trial: 10610746
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral diltiazem 180 mg/day for 1 month before and 2 months after cardioversion)
Trial: 3529953
Drug: Regular aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aspirin (325 mg)
Trial: 29432648
Drug: Pilocarpine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (5 mg, 10 drops orally, three times daily for 12 weeks)
Trial: 29432648
Drug: Artificial saliva
RxNorm normalized name: ARTIFICIAL SALIVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial saliva (10 drops orally, three times daily for 12 weeks)
Trial: 26678717
Drug: Neuromuscular taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular taping (NMT) and standard physical therapy programme (SPTP)
Trial: 26678717
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy programme (SPTP)
Trial: 19887674
Drug: NS-398 (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS-398 (selective COX-2 inhibitor) added in vitro
Trial: 15817865
Drug: Home-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based therapy with RUTF
Trial: 1445513
Drug: Diuretic (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (hydrochlorothiazide 25 mg or 50 mg plus amiloride 2.5 mg or 5 mg daily)
Trial: 1445513
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker (atenolol 50 mg daily)
Trial: 4061343
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg zinc added to daily vitamin and mineral supplements)
Trial: 4061343
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (similar daily vitamin and mineral supplements without zinc)
Trial: 24849434
Drug: DC-CIK immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC-CIK immunotherapy combined with TACE
Trial: 22984155
Drug: Inhaled fentanyl
RxNorm normalized name: fentanyl Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fentanyl 25 µg
Trial: 22984155
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl 25 µg
Trial: 22984155
Drug: Inhaled fentanyl
RxNorm normalized name: fentanyl Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fentanyl (50 to 300 µg)
Trial: 20819419
Drug: Intraperitoneal instillation
RxNorm normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal instillation of 2 mg/kg ropivacaine
Trial: 18281049
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for 3 months
Trial: 18281049
Drug: Ethinyl estradiol-cyproterone
RxNorm normalized name: cyproterone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl estradiol-cyproterone acetate (EE/CPA) treatment for 3 months
Trial: 10598759
Drug: Topical 5-aminolaevulinic
RxNorm normalized name: methyl 5-aminolevulinate Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-aminolaevulinic acid photodynamic therapy (ALA-PDT)
Trial: 7564784
Drug: IFN‐alpha (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha (6 MU three times weekly for 12‐24 weeks)
Trial: 1940881
Drug: Alpha interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha interferon (5-6 million units daily)
Trial: 30346560
Drug: Modified S-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified S-1 treatment (reduced initial dose of S-1 by ≥ 1 level compared with the standard dose)
Trial: 26176649
Drug: Hot compresses
RxNorm normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot compresses (40°C) applied to the lumbar area for 5 hours daily for 2 weeks
Trial: 22963328
Drug: Multimodal training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal training intervention (MTI) consisting of daily endurance and twice-a-week strength training
Trial: 19343362
Drug: Coconut and
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [Hand Sanitizer Coconut and Lime 3oz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut and anise spray
Trial: 19343362
Drug: Permethrin 0.43%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permethrin 0.43% lotion
Trial: 12423713
Drug: Metoprolol (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (high-dose, 1-year course)
Trial: 12423713
Drug: Carvedilol (high-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (high-dose, 1-year course)
Trial: 8584309
Drug: Combined diphtheria-tetanus
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined diphtheria-tetanus vaccine administered at 3, 5, and 12 months of age.
Trial: 29071332
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral administration of ticagrelor, 180mg
Trial: 29071332
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (chewing and standard oral administration)
Trial: 17466465
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention designed to decrease sexual and injection risk behaviors, delivered in six sessions.
Trial: 14984453
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.15 U/kg body weight)
Trial: 14984453
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (0.15 U/kg body weight)
Trial: 11157184
Drug: AR-R15896AR 250
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-R15896AR 250 mg loading dose
Trial: 11157184
Drug: AR-R15896AR 120
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-R15896AR 120 mg maintenance dose
Trial: 27364771
Drug: Veledimex (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veledimex (oral activator ligand) administered in Labrasol slurry and F-22 capsule formulations
Trial: 27364771
Drug: Veledimex (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veledimex (oral activator ligand) administered once daily for 14 days
Trial: 27364771
Drug: Veledimex (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veledimex (overall treatment)
Trial: 24250307
Drug: Diet regimen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet regimen, exercise training, and medical treatment for two months
Trial: 18344107
Drug: Sustained-release acetaminophen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release acetaminophen, 1300 mg orally q8h for 11 doses
Trial: 11878530
Drug: 4% gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% gelatin solution (Gelofusine) 15 ml kg(‐1) i.v. (colloid group)
Trial: 9181155
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg hyperbaric lidocaine 5%
Trial: 9181155
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hyperbaric lidocaine 5%
Trial: 9181155
Drug: Both dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosage groups (75 mg and 100 mg)
Trial: 3596336
Drug: Ranitidine 2
RxNorm normalized name: ranitidine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 2 X 150 mg per day
Trial: 30526588
Drug: Two rounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two rounds of mass drug administration (MDA) with dihydroartemisinin‐piperaquine and single low‐dose primaquine, administered 4 weeks apart in May‐June 2016.
Trial: 15618781
Drug: Terlipressin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1 mg)
Trial: 11875582
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate (10 mmol) infusion
Trial: 10448830
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) 23‐35 mg/kg/day, t.i.d.
Trial: 2149388
Drug: cilazapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril (2.5 to 5.0 mg)
Trial: 2149388
Drug: hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (25 to 50 mg)
Trial: 364285
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vincristine and prednisone with streptonigrin
Trial: 364285
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vincristine and prednisone with cyclophosphamide
Trial: 30554751
Drug: Home-based screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based screening for abnormal vaginal flora and urinary tract infections; treatment with oral clindamycin (300 mg twice daily for 5 days) for abnormal vaginal flora and cefixime (400 mg once daily for 3 days) or oral nitrofurantoin (100 mg twice daily for 7 days) for urinary tract infections.
Trial: 30554751
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received standard antenatal and postnatal care without the specific screening and treatment for infections.
Trial: 30554751
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of abnormal vaginal flora and urinary tract infections in the intervention group.
Trial: 28072802
Drug: 10% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sodium chloride solution added to lidocaine, triamcinolone, and hyaluronidase (hypertonic group)
Trial: 28072802
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional transforaminal epidural steroid injections)
Trial: 19270861
Drug: Warmed contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed contrast material (Omnipaque [Iohexol] 350 mg I/mL at 37 degrees C)
Trial: 19270861
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature contrast material (Omnipaque [Iohexol] 350 mg I/mL at 24 degrees C)
Trial: 15465995
Drug: Low-dose omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose omega-3 fatty acids
Trial: 11465517
Drug: Mirtazapine treatment
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine treatment after a 4-day washout period
Trial: 182347
Drug: Estrogen treatments
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen treatments (Premarin, Provera, Provera and diethylstilbestrol, diethylstilbestrol alone)
Trial: 19657295
Drug: 1.5 mg.kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg.kg BW caffeine
Trial: 19657295
Drug: 3 mg.kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg.kg BW caffeine
Trial: 17244923
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 15 mg x kg(‐1) before heparin and before protamine injection
Trial: 14746622
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% used twice daily
Trial: 14746622
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (reactive treatment)
Trial: 11719310
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nocturnal oxygen therapy)
Trial: 25633497
Drug: Oral reduced
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral reduced L-glutathione (GSH) 65 mg · kg(‐1) · day(‐1) divided into 3 doses per day for 6 months
Trial: 25633497
Drug: Oral reduced
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral reduced L-glutathione (GSH)
Trial: 20184615
Drug: Psychotropic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic medication (mostly pimozide)
Trial: 14570168
Drug: Oral temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral temperature
Trial: 10199876
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) - 8 mg/min
Trial: 7774991
Drug: Metoprolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (40 mg)
Trial: 25803679
Drug: 10 J/cm²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 J/cm² IPL treatment
Trial: 25803679
Drug: 13 J/cm²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 J/cm² IPL treatment
Trial: 25803679
Drug: Both 10J
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 10J and 13J IPL treatment
Trial: 24105697
Drug: Magnesium (50
RxNorm normalized name: magnesium gluconate 27 mg magnesium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (50 mg/kg bolus followed by 50 mg/kg infusion for 3 hours)
Trial: 27461675
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Paclitaxel 175 mg/m² on day 1 and Carboplatin 450 mg on day 2 (PC)
Trial: 27461675
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Docetaxel and Cisplatin 75 mg/m² each on day 1 and Ifosfamide 2 g/m² on day 1-3 along with Mesna (docetaxel-ifosfamide-cisplatin)